Therapeutic candidates and patient samples can be analyzed ‘in a fraction of the time it would normally take’ thanks to newly patented single-molecule imaging technology.
Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.
Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator.
Courts continue to rule in favor of Lilly’s lung cancer treatment patent, as the District Court for Appeals concludes generic producers like Dr Reddy’s to be potentially infringing.
Novartis exercises its option to license Ionis’ RNA-targeting cardiovascular drug, adding to its cardiovascular treatment portfolio, as Entresto reaches the three-year mark on its patent.
The US Court of Appeals for the Federal Circuit removed the injunction against Dr. Reddy’s, which prevented the company from selling its Suboxone generic.
The clinical development services provider Phesi is looking to patent its method and system for developing clinical trial protocols – which enables faster patient enrollment and study completion, says CEO.
The European Patent Office has upheld protection relating to Gilead’s costly Hepatitis C drug Sovaldi, which Médecins du Monde claims prevents patients from receiving affordable treatment.
Ncardia has entered into a non-exclusive licensing agreement with Evotec through which the drug discovery solutions company will gain access to Ncardia’s stem cell derived cellular disease modeling IP.
Clinerion has filed a patent for a technology that matches anonymized records with corresponding hospital medical records to identify potential clinical trial participants.
Arecor has entered a £45m ($56m) agreement to develop once daily injection of Cadila Pharmaceuticals’ basal insulin product using its reformulation technology.
DSM Sinochem Pharmaceuticals has licensed enzyme-based antibiotic production IP to Sandoz and accused Sinopharm Weiqida Pharmaceutical of patent infringement.
The Medicines Company announced last week that its Angiomax patent has been upheld – an 'important court decision' which affirms that working with CMOs won’t invalidate a company's patent.
The US Patent and Trademark Office (USPTO) has refused to review a challenge to Acorda Therapeutics’ patents from a group trying to block “abusive” IP claims.
US intellectual property (IP) rules and a string of recent court cases are reducing the types of inventions pharma companies can patent, and “calling into question entire portfolios,” says a specialist lawyer.
Makers of branded drugs are finding ways to extend their marketing authorisation by patenting not only molecules, but patient screening methods and ways of proving bioequivalence.
A lack of understanding and commentary on proceedings may be putting some pharma firms off opting into the UK’s Patent Box scheme, according to a legal expert.
Marinomed Biotechnologies is set to take on the ‘common cold’ in China with a new patent for an anti-viral polymer technology that prevents rhinovirus infection.
Legal battles, patent acquisitions and R&D dominate in-pharmatechnologist.com’s round up of developments in drug delivery this week with news from MonoSol, Acacia and a US University team working on GSK’s Relenza.
The USPTO has rejected MonoSol RX’s claims that production methods for a cancer pain patch developed by BioDelivery Sciences (BDSI) infringe on manufacturing techniques it uses to make its own drug delivery films.
Sartorius Stedium Biotech (SSB) and GE Healthcare Life Sciences say new cross licensing deal will aid development of their respective biomanufacturing tech offerings.
Marina Biotech has strengthened its nucleic acid-peptide drug delivery platform after being granted the allowance for patents application of a library of novel peptides.
The Pharmaceutical Research and Manufacturers of America (PhRMA) has welcomed proposed changes to US patent laws that would alter the basis for patent awards.
Improving safety and efficacy coupled with drug industry desire for “stronger” patents will drive growth of the biologics sector over the next five years, according to new research.
Geron says the USPTO appeals board granted a request to declare “interference” between a patent application owned by the firm and one issued to Novocell in March.
Bio-Path Holdings has signed an exclusive licence to develop a liposomal tumour targeting technology that delivers antisense and FAK siRNA and cuts toxicity.
Bangladesh represents a “huge opportunity” to pharma, according to the CEO of Amreteck Pharma who believes that CMOs will be attracted by the low costs, which undercut China, and help the industry grow to $10bn (€6.9m) in 10 years.
A committee appointed by the Indian government has submitted a report into whether patent issues around microorganisms and NCEs are in compliance with TRIPS.
A UK judge has warned against the European Commission making rash changes following its report into big pharma blocking generics, arguing that it could damage development of new drugs.
The generic pharmaceutical industry has given short shrift to the
latest congressional attempt to construct a viable approval pathway
for biosimilars in the US.
Australian drug delivery specialist Acrux has reported positive
results in Phase II trials of its innovative under-arm lotion
formulation for testosterone replacement therapy.
The ongoing intellectual property tussle between Pall and Entegris
continues with Pall claiming Entegris' Impact filter cartridge line
infringes four Pall patents.
LabTechnologist.com presents its periodic round up of recent
industry news with new developments at Agilent, Beckman Coulter,
Carl Zeiss, DuPont, Luminex and PerkinElmer.
Finnish company DelSitech has signed a license agreement with Bayer
Innovation, a subsidiary of the Germany's Bayer group, in a deal
that could lead to the creation of a new generation of wound care
products.
Biopharmaceutical firm Nektar has agreed to fork out $25m (€20m) to
settle a patent lawsuit by the University of Alabama in Huntsville
(UAH) concerning the company's PEGylation delivery technology
currently used in eight approved...
Biophan has filed the first patent to come out of its newly-formed
relationship with NaturalNano to develop new and improved ways of
controlled-release drug delivery.
A collaboration between Anachem and chemists within the
pharmaceutical industry has resulted in the launch of the new
ReactArray Solo, which is designed to provide faster, more
efficient polymorph screening to aid drug patent protection...
